TB vaccine impact hinges on blocking asymptomatic infectious disease

Tuberculosis remains a leading cause of infectious disease death worldwide, and new vaccines are seen as a promising route to reduce that burden. But estimates of how much good a vaccine will do rely on assumptions about where in the course of TB the vaccine works and how TB progresses in people — assumptions that may be wrong. Rebecca A. Clark and colleagues set out to explore how sensitive projected vaccine benefits are to those uncertainties. They built a mathematical, dynamic compartmental model of TB for India that explicitly includes early stages of the disease, including asymptomatic phases. The team compared several vaccine scenarios: one vaccine that only prevents progression to infectious symptomatic disease, one that prevents any infectious disease (symptomatic or not), and one that prevents any disease stage. Each scenario assumed a vaccine that is 50% effective for 10 years. They estimated how many disease episodes would be averted between 2030 and 2050 compared with a situation where no new vaccine is introduced, aiming to see how different kinds of vaccine effects change outcomes over time.

To test these scenarios the researchers used a dynamic compartmental TB model for India that captures early, asymptomatic stages of infection and disease, and they ran projections under the same vaccine efficacy assumption: 50% protection lasting 10 years. They measured the proportion of symptomatic TB episodes averted by each vaccine scenario. In the short term — over three years — there was little difference between vaccines that only prevented progression to infectious symptomatic disease, those that prevented any infectious disease, and those that prevented any disease: they averted 1.8%, 2.3%, and 2.4% of cumulative symptomatic disease episodes, respectively. However, over a longer 20-year horizon the differences grew substantially. Compared with the vaccine that only prevented infectious symptomatic disease, vaccines that prevented any infectious disease or any disease averted much larger proportions of symptomatic episodes: 8.2%, 21.0%, and 25.1%, respectively. The model attributes much of this larger long-term impact to stopping continued transmission from people with infectious asymptomatic TB.

These findings suggest that a vaccine’s population-level value may hinge on whether it reduces not just symptomatic TB but also infectious asymptomatic disease. In the short term, focusing on symptomatic disease prevention produces similar projected benefits, but over decades stopping asymptomatic infectious cases can substantially cut transmission and resulting illness. That matters for how trials are designed and what they measure: if asymptomatic infectious disease drives ongoing spread, vaccines that reduce that stage will offer greater long-term returns. The authors conclude that TB vaccine trials should measure effects on infectious asymptomatic disease to give better estimates of potential impact. They also call for more data collection to improve understanding of how transmissible, how harmful, and how common asymptomatic disease is, because those unknowns change long-term projections and policy-relevant decisions about vaccine use.